GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 68 Category No. of Shares % Mutual Funds 7064446 4.17 Financial Institutions / Banks / Insurance Companies 11123834 6.57 Foreign Institutional Investors / NRI / OCB 4334364 2.56 Bodies Corporates 924518 0.54 Foreign Nationals 618 0.00 Individuals 17969918 10.61 Others 933812 0.55 Total 169,406,034 100.00 Registrar and Share Transfer Agent KFin Technologies Limited (Formerly known as KFin Technologies Private Limited) Unit: GlaxoSmithKline Pharmaceuticals Limited Selenium Tower B, Plot No 31 and 32 Gachibowli, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana – 500032 Tel No.: 040 - 67162222, Fax No.: 040 - 23001153 Contact Person: Mr. Premkumar Nair Email ID: einward.ris@kfintech.com Share transfer system The Directors and Company Secretary are authorized by the Board severally to approve transfers, which are noted at subsequent Board Meetings. In terms of amended Regulation 40 of Listing Regulations w.e.f. 1 st April, 2019, transfer of securities in physical form shall not be processed unless the securities are held in the demat mode with a Depository Participant. Further, with effect from 24 th January, 2022, SEBI has made it mandatory for listed companies to issue securities in demat mode only while processing any investor service requests viz. issue of duplicate share certificates, exchange/sub-division/ splitting/consolidation of securities, transmission/ transposition of securities. Vide its Circular dated 25 th January, 2022, SEBI has clarified that listed entities/ RTAs shall now issue a Letter of Confirmation in lieu of the share certificate while processing any of the aforesaid investor service request. Dematerialisation of shares and liquidity 98.90% of the paid-up capital has been dematerialised as on 31 March 2022. Glaxo Group Limited, GlaxoSmithKline Pte Limited, Eskaylab Limited and Burroughs Wellcome International Limited, who jointly hold 75.00% of the paid-up share capital of the Company, hold their shares in the dematerialised form. Outstanding GDRs/ADRs/ Warrants or any convertible instruments conversion date and likely impact on equity Not issued Address for correspondence Members correspondence should be addressed to the Company’s Registrar and Share Transfer Agent at the address mentioned above. Members may also contact Mr. Ajay Nadkarni, Company Secretary, at the Registered office of the Company for any assistance. Tel. Nos. 022- 24959595 Extension 433/434/415, Email ID : ajay.a.nadkarni@gsk.com Members holding shares in electronic mode should address all their correspondence to their respective Depository Participant. Plant A-10, M I D C Area - Ambad, Nashik, Maharashtra 422001 Annexure ‘C’ Report on Corporate Governance